Paul Mccormac PhD

Paul McCormac, Ph.D., joined LEXEO Therapeutics as SVP Technical Operations in March 2021. LEXEO Therapeutics is a New York City-based clinical-stage gene therapy biotechnology company with a focus on hereditary and acquired diseases of high unmet need. Prior to LEXEO, Dr. McCormac was an Executive Director, Medicinal sciences category lead for Pfizer Rare Disease. He represented CMC/product development to Pfizer‘s Rare Disease Business and Research Units with a major focus on Pfizer’s Gene Therapy CMC strategy. From 2008 to 2016 Paul was a product development leader for Pfizer’s manufacturing organization, leading large molecule products in late development and commercialization. Prior to joining Pfizer Paul was a director of process development for Avecia Biotechnology a leading contract manufacturer of oligonucleotide therapeutics.